Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.69 |
| ▸ | NQO2 | P16083 | 4/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 4/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6817116 | 0.92 | MTNR1A (0.59) | MTNR1AMTNR1BCHRNB2CHRNA4 | |
| SCHEMBL7219800 | 0.87 | MTNR1A (0.73) | MTNR1ANQO2MTNR1B | |
| SCHEMBL7219370 | 0.85 | MTNR1A (0.70) | MTNR1ANQO2MTNR1B | |
| SCHEMBL8435177 | 0.84 | MTNR1A (0.69) | MTNR1ANQO2MTNR1BCHRNB2CHRNA4 | |
| SCHEMBL8433848 | 0.83 | MTNR1A (0.67) | MTNR1ANQO2MTNR1B | |
| SCHEMBL5335761 | 0.82 | MTNR1A (1.00) | MTNR1ANQO2MTNR1B | |
| SCHEMBL5582823 | 0.81 | ITGB3 (0.66) | MTNR1AITGB3ITGA2BDGAT1 | |
| SCHEMBL8432639 | 0.79 | MTNR1A (0.62) | MTNR1ANQO2MTNR1BCHRNB2CHRNA4 | |
| SCHEMBL8432255 | 0.79 | MTNR1A (0.62) | MTNR1ANQO2MTNR1B | |
| SCHEMBL7066927 | 0.79 | MTNR1A (0.62) | MTNR1ANQO2MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552044-B2 | Dopamine receptors | H. LUNDBECK A/S (DK) | 2003-04-22 | — | — | US | disclosed |
| EP-0946542-B1 | INDANE OR DIHYDROINDOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2002-10-09 | — | — | EP | disclosed |
| US-6352988-B2 | HIGH AFFINITY FOR D4 RECEPTORS; TREATMENT OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, DEPRESSION, ALCOHOL ABUSE, IMPULSE CONTROL DISORDERS, AGGRESSION | H. LUNDBECK A/S (DK) | 2002-03-05 | — | — | US | disclosed |
| US-20010021777-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-13 | — | — | US | disclosed |
| US-20010020095-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-06 | — | — | US | disclosed |
| US-6262087-B1 | HAVE HIGH AFFINITY FOR D4 RECEPTORS; USEFUL IN THE TREATMENT OF CERTAIN PSYCHIATRIC AND NEUROLOGIC DISORDERS, INCLUDING PSYCHOSIS, DEPRESSION AND ANXIETY. | H. LUNDBECK A/S (DK) | 2001-07-17 | — | — | US | disclosed |
| EP-0946542-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028293-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H.LUNDBECK A/S (DK) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020095-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | MTNR1A 42/4885NQO2 830/4885MTNR1B 72/4885 |
| US-20010021777-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | MTNR1A 42/4885NQO2 830/4885MTNR1B 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.